Хронический эндометрит: современные взгляды на проблему
- Авторы: Шуршалина А.В1
 - 
							Учреждения: 
							
- Американский медицинский центр, Москва
 
 - Выпуск: Том 13, № 6 (2011)
 - Страницы: 36-39
 - Раздел: Статьи
 - URL: https://bakhtiniada.ru/2075-1753/article/view/93368
 - ID: 93368
 
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаСписок литературы
- Корсак, В.С., Забелкина О.В., Исакова Э.В. Исследование эндометрия у пациенток с трубно - перитонеальным бесплодием на этапе подготовки к ЭКО. Проблемы репродукции. 2005; 2: 39–42.
 - Сидельникова В.М. Привычная потеря беременности. М.: Триада-Х, 2000.
 - Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: руководство для врачей. М.: МИА, 2002.
 - Buckley C.H., Fox H. Biopsy pathology of the endometrium. NY: Arnold, 2002.
 - Шуршалина А.В. Хронический эндометрит. Автореф. дис. ... д - ра мед. наук. М., 2007.
 - Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morbidity and Mortality Weekly Report (MMWR) 2010; 59 (RR-12): 1–114.
 - Демидов В.Н., Гус А.И. Эхография органов малого таза у женщин. Вып. III. Патология полости матки и эндометрия. ВМК: практ. пособие. М., 2000; с. 16–36.
 - Noyes R.W., Hertig A.T., Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1: 3–25.
 - Novak E.R.,Woodruff J.D. Gynecologic and obstetric pathology. Philadelphia 1999; 241–5.
 - Ness R.B., Soper D.E., Holley R.L. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186 (5): 929–37.
 - Стругацкий В.М., Силантьева Е.С. Акуш. и гинекол. 2002; 6: 51–3.
 - Haggerty C.L., Ness R.B. Diagnosis and treatment of pelvic inflammatory disease. Womens Health (Lond Engl) 2008; 4 (4): 383–97.
 - Morikawa K, Zhang J, Nonaka M, Morikawa S. Modulatory effect of macrolide antibiotics on the Th1 - and Th2 - type cytokine production. Int J Antimicrob Agents 2002; 19 (1): 53–9.
 - Bradshaw C.S., Chen M.Y., Fairley C.K. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS ONE 2008; 3 (11): e3618.
 - Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. Bjog 2010; 117 (3): 361–4.
 - Jaiyeoba O, Lazenby G, Soper D.E. Recommendations and rationale for the treatment of pelvic inflammatory disease. Expert review of anti - infective therapy 2011; 9 (1): 61–70.
 - Bhengraj A.R., Vardhan H, Srivastava P, Salhan S et al. Decreased Susceptibility to Azithromycin and Doxycycline in Clinical Isolates of Chlamydia trachomatis Obtained from Recurrently Infected Female Patients in India. Chemotherapy 2010; 56 (5): 371–7.
 - Sternak S.L., Skerk V. [Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice]. Med Glas Ljek komore Zenicko - doboj kantona 2010; 7 (1): 26–31.
 - Segreti J, Kapell K.S., Trenholme G.M. In vitro activity of beta - lactam drugs and sulbactam against Chlamydia trachomatis. Diagnostic microbiology and infectious disease 1992; 15 (4): 371–3.
 - Czeizel A.E., Rockenbauer M, Olsen J, Sorensen H.T. A case - control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta obstetricia et gynecologica Scandinavica 2000; 79 (3): 234–7.
 - Oshima T, Iwadare M. Josamycin propionate. 5. Teratological studies. The Japanese journal of antibiotics 1973; 26 (2): 148–53.
 - Ikezaki S, Nishikawa A, Furukawa F et al. A 13-week subchronic toxicity study of josamycin in F344 rats. Eisei Shikenjo Hokoku 1995; (113): 44–50.
 - Miura M, Morino T, Endo H, Shiraiwa K et al. Comparative toxicity study of rokitamycin and josamycin in rats. Jpn J Antibiot 1987; 40 (3): 588–601.
 - Kuriaki K, Miki H, Sejima Y, Shibata M et al. New antibiotics, Josamycin. V. Studies on toxicity of Josamycin. Jpn J Antibiot 1969; 22 (3): 219–25.
 - Schaefer C, Hannemann D, Meister R. Post - marketing surveillance system for drugs in pregnancy – 15 years experience of ENTIS. Reproductive toxicology. Elmsford. NY, 2005; 20 (3): 331–43.
 
Дополнительные файлы
				
			
						
					
									